SK18772001A3 - Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie - Google Patents

Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie Download PDF

Info

Publication number: SK18772001A3
Authority: SK; Slovakia
Prior art keywords: medicament; thresholds; figures; manufacture; gray scale
Prior art date: 1999-06-16

Application number

SK1877-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Raouf Rekik

Original Assignee

Rekik Elyes Ben Mohamed Raouf

Raouf Rekik

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-16

Filing date

2000-06-16

Publication date

2002-04-04

1999-12-06 Priority claimed from FR9915359A external-priority patent/FR2794975A1/fr

2000-06-16 Application filed by Rekik Elyes Ben Mohamed Raouf, Raouf Rekik filed Critical Rekik Elyes Ben Mohamed Raouf

2002-04-04 Publication of SK18772001A3 publication Critical patent/SK18772001A3/sk

Links

239000003814 drug Substances 0.000 title claims abstract description 37
230000000324 neuroprotective effect Effects 0.000 title claims abstract description 8
230000003289 retinoprotective effect Effects 0.000 title claims abstract description 8
229940079593 drug Drugs 0.000 title claims description 13
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims abstract description 25
229960003401 ramipril Drugs 0.000 claims abstract description 25
230000004304 visual acuity Effects 0.000 claims abstract description 24
230000002207 retinal effect Effects 0.000 claims abstract description 19
KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 claims abstract description 18
230000004382 visual function Effects 0.000 claims abstract description 17
230000000007 visual effect Effects 0.000 claims abstract description 16
229960002231 ramiprilat Drugs 0.000 claims abstract description 14
201000001119 neuropathy Diseases 0.000 claims abstract description 11
230000007823 neuropathy Effects 0.000 claims abstract description 11
208000033379 Chorioretinopathy Diseases 0.000 claims abstract description 10
206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 10
208000002780 macular degeneration Diseases 0.000 claims abstract description 10
230000003412 degenerative effect Effects 0.000 claims abstract description 6
208000001491 myopia Diseases 0.000 claims abstract description 6
230000004379 myopia Effects 0.000 claims abstract description 6
206010058990 Venous occlusion Diseases 0.000 claims abstract description 3
238000011282 treatment Methods 0.000 claims description 29
208000010412 Glaucoma Diseases 0.000 claims description 17
239000003112 inhibitor Substances 0.000 claims description 13
102000004190 Enzymes Human genes 0.000 claims description 12
108090000790 Enzymes Proteins 0.000 claims description 12
229960002680 enalaprilat Drugs 0.000 claims description 12
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims description 12
108010066671 Enalaprilat Proteins 0.000 claims description 11
230000000052 comparative effect Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
230000002441 reversible effect Effects 0.000 claims description 10
230000005764 inhibitory process Effects 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 7
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 7
208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
239000006210 lotion Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
101800000733 Angiotensin-2 Proteins 0.000 claims description 5
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 5
238000006317 isomerization reaction Methods 0.000 claims description 5
241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
229950006323 angiotensin ii Drugs 0.000 claims description 4
210000001367 artery Anatomy 0.000 claims description 4
230000000593 degrading effect Effects 0.000 claims description 4
239000002532 enzyme inhibitor Substances 0.000 claims description 4
229940125532 enzyme inhibitor Drugs 0.000 claims description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
206010019899 Hereditary retinal dystrophy Diseases 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
230000000304 vasodilatating effect Effects 0.000 claims description 3
210000003462 vein Anatomy 0.000 claims description 3
208000017532 inherited retinal dystrophy Diseases 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
102000005862 Angiotensin II Human genes 0.000 claims 1
101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 claims 1
102100029365 Piwi-like protein 2 Human genes 0.000 claims 1
GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 claims 1
208000033808 peripheral neuropathy Diseases 0.000 abstract description 7
108010080213 vascular factor Proteins 0.000 abstract description 7
210000001525 retina Anatomy 0.000 abstract description 6
230000007170 pathology Effects 0.000 abstract description 4
150000001875 compounds Chemical class 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000006872 improvement Effects 0.000 description 21
230000035945 sensitivity Effects 0.000 description 21
230000004438 eyesight Effects 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 11
208000035475 disorder Diseases 0.000 description 9
210000001328 optic nerve Anatomy 0.000 description 8
201000004569 Blindness Diseases 0.000 description 7
201000010099 disease Diseases 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000002792 vascular Effects 0.000 description 7
230000007423 decrease Effects 0.000 description 6
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
239000005541 ACE inhibitor Substances 0.000 description 5
201000007737 Retinal degeneration Diseases 0.000 description 5
230000004393 visual impairment Effects 0.000 description 5
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
102400000345 Angiotensin-2 Human genes 0.000 description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
230000004087 circulation Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
230000004410 intraocular pressure Effects 0.000 description 4
230000000302 ischemic effect Effects 0.000 description 4
208000018769 loss of vision Diseases 0.000 description 4
231100000864 loss of vision Toxicity 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
101800000734 Angiotensin-1 Proteins 0.000 description 3
102400000344 Angiotensin-1 Human genes 0.000 description 3
206010003694 Atrophy Diseases 0.000 description 3
241000238413 Octopus Species 0.000 description 3
230000037444 atrophy Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000000049 pigment Substances 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
210000001210 retinal vessel Anatomy 0.000 description 3
208000014087 Chorioretinal disease Diseases 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
206010038903 Retinal vascular occlusion Diseases 0.000 description 2
206010039729 Scotoma Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
238000002583 angiography Methods 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
238000013534 fluorescein angiography Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
230000004386 ocular blood flow Effects 0.000 description 2
229940023490 ophthalmic product Drugs 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
206010025415 Macular oedema Diseases 0.000 description 1
235000002779 Morchella esculenta Nutrition 0.000 description 1
240000002769 Morchella esculenta Species 0.000 description 1
208000001140 Night Blindness Diseases 0.000 description 1
201000010183 Papilledema Diseases 0.000 description 1
208000037111 Retinal Hemorrhage Diseases 0.000 description 1
206010038886 Retinal oedema Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000003732 agents acting on the eye Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000004377 improving vision Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
229960004657 indocyanine green Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
201000010230 macular retinal edema Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000649 photocoagulation Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
201000011195 retinal edema Diseases 0.000 description 1
210000001957 retinal vein Anatomy 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000004855 vascular circulation Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

SK1877-2001A 1999-06-16 2000-06-16 Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie SK18772001A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
TN99122		1999-06-16
FR9915359A FR2794975A1 (fr)	1999-06-16	1999-12-06	Medicaments opthalmologiques neuro et retino-protecteurs
PCT/FR2000/001679 WO2000076499A2 (fr)	1999-06-16	2000-06-16	Medicaments ophtalmologiques neuro-et retino-protecteurs

Publications (1)

Publication Number	Publication Date
SK18772001A3 true SK18772001A3 (sk)	2002-04-04

Family

ID=26235177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1877-2001A SK18772001A3 (sk)	1999-06-16	2000-06-16	Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie

Country Status (20)

Country	Link
US (1)	US7049340B1 (da)
EP (1)	EP1185255B1 (da)
JP (1)	JP2003501461A (da)
AT (1)	ATE424819T1 (da)
AU (1)	AU6449000A (da)
BR (1)	BR0011714A (da)
CA (1)	CA2376909A1 (da)
CZ (1)	CZ20014516A3 (da)
DE (1)	DE60041765D1 (da)
DK (1)	DK1185255T3 (da)
ES (1)	ES2324200T3 (da)
HU (1)	HUP0201478A3 (da)
MA (1)	MA26798A1 (da)
MX (1)	MXPA01012907A (da)
NO (1)	NO20016088L (da)
PL (1)	PL352365A1 (da)
SI (1)	SI1185255T1 (da)
SK (1)	SK18772001A3 (da)
TR (1)	TR200103665T2 (da)
WO (1)	WO2000076499A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2826276A1 (fr) *	2001-06-20	2002-12-27	Raouf Rekik	Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
US7858611B2 (en)	2006-05-09	2010-12-28	Braincells Inc.	Neurogenesis by modulating angiotensin
EP2382975A3 (en) *	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
TNSN08110A1 (en) *	2008-03-11	2009-07-14	Rekik Raouf Dr	Drug delivery to the anterior and posterior segment of the eye from drops
TN2010000566A1 (en) *	2010-12-03	2012-05-24	Rekik Raouf	Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
RU2471454C2 (ru) *	2010-12-14	2013-01-10	Валерий Викторович Педдер	Способ лечения дистрофических заболеваний сетчатки глаза
JP6238977B2 (ja) *	2012-06-29	2017-11-29	ラオフ・レキク	視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3381850D1 (de) *	1982-12-27	1990-10-04	Schering Corp	Pharmazeutische zusammensetzung.
DE3410732A1 (de) *	1984-03-23	1985-09-26	Hoechst Ag, 6230 Frankfurt	Methode zur behandlung des glaukoms
US4656188A (en) *	1985-10-09	1987-04-07	Merck & Co., Inc.	Ace inhibitors in macular degeneration
JPH05306296A (ja) *	1992-04-24	1993-11-19	Marino Forum 21	魚類由来ペプチドとその製法
AU2089099A (en) *	1998-01-16	1999-08-02	Alcon Laboratories, Inc.	Topical administration of angiotensin-converting enzyme inhibitors

2000
- 2000-06-16 DE DE60041765T patent/DE60041765D1/de not_active Expired - Lifetime
- 2000-06-16 CZ CZ20014516A patent/CZ20014516A3/cs unknown
- 2000-06-16 CA CA002376909A patent/CA2376909A1/fr not_active Abandoned
- 2000-06-16 MX MXPA01012907A patent/MXPA01012907A/es unknown
- 2000-06-16 HU HU0201478A patent/HUP0201478A3/hu unknown
- 2000-06-16 PL PL00352365A patent/PL352365A1/xx not_active Application Discontinuation
- 2000-06-16 DK DK00951603T patent/DK1185255T3/da active
- 2000-06-16 AU AU64490/00A patent/AU6449000A/en not_active Abandoned
- 2000-06-16 SK SK1877-2001A patent/SK18772001A3/sk unknown
- 2000-06-16 JP JP2001502832A patent/JP2003501461A/ja active Pending
- 2000-06-16 WO PCT/FR2000/001679 patent/WO2000076499A2/fr not_active Ceased
- 2000-06-16 US US10/018,235 patent/US7049340B1/en not_active Expired - Lifetime
- 2000-06-16 TR TR2001/03665T patent/TR200103665T2/xx unknown
- 2000-06-16 SI SI200031031T patent/SI1185255T1/sl unknown
- 2000-06-16 BR BR0011714-5A patent/BR0011714A/pt not_active Application Discontinuation
- 2000-06-16 AT AT00951603T patent/ATE424819T1/de active
- 2000-06-16 EP EP00951603A patent/EP1185255B1/fr not_active Expired - Lifetime
- 2000-06-16 ES ES00951603T patent/ES2324200T3/es not_active Expired - Lifetime
2001
- 2001-12-10 MA MA26439A patent/MA26798A1/fr unknown
- 2001-12-13 NO NO20016088A patent/NO20016088L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0201478A3 (en)	2004-05-28
US7049340B1 (en)	2006-05-23
ATE424819T1 (de)	2009-03-15
CZ20014516A3 (cs)	2002-05-15
DK1185255T3 (da)	2009-07-06
WO2000076499A2 (fr)	2000-12-21
HUP0201478A2 (hu)	2002-11-28
EP1185255A2 (fr)	2002-03-13
CA2376909A1 (fr)	2000-12-21
MA26798A1 (fr)	2004-12-20
NO20016088D0 (no)	2001-12-13
JP2003501461A (ja)	2003-01-14
BR0011714A (pt)	2002-03-05
WO2000076499A3 (fr)	2001-05-17
ES2324200T3 (es)	2009-08-03
EP1185255B1 (fr)	2009-03-11
MXPA01012907A (es)	2003-06-24
PL352365A1 (en)	2003-08-25
SI1185255T1 (sl)	2009-08-31
TR200103665T2 (tr)	2002-10-21
DE60041765D1 (de)	2009-04-23
AU6449000A (en)	2001-01-02
NO20016088L (no)	2002-02-12

Publication	Publication Date	Title
CA1332811C (en)	1994-11-01	Treatment of ocular hypertension with class i calcium channel blocking agents
Bresnick	1983	Diabetic maculopathy: a critical review highlighting diffuse macular edema
Perry et al.	2003	Latanoprost: an update of its use in glaucoma and ocular hypertension
JP5579079B2 (ja)	2014-08-27	黄斑浮腫治療用ジフルプレドナート点眼剤
OA12720A (en)	2006-06-27	Methods for treating ocular neovascular diseases.
WO2010113753A1 (ja)	2010-10-07	ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
MX2012007941A (es)	2012-09-12	Farmaceutico para impedir o tratar alteraciones acompañadas por angiogenesis ocular y/o permeabilidad vascular ocular elevada.
US5431907A (en)	1995-07-11	Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents
US5212168A (en)	1993-05-18	Method of and solution for treating glaucoma
US4904649A (en)	1990-02-27	Method and solution for treating glaucoma
Rouland et al.	2002	Timolol 0.1% gel (Nyogel 0.1%®) once daily versus conventional timolol 0.5% solution twice daily: A comparison of efficacy and safety
SK18772001A3 (sk)	2002-04-04	Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie
AU761092B2 (en)	2003-05-29	Use of staurosporine derivatives for treating ocular neovascular diseases
Winterkorn et al.	1995	Recovery from ocular ischemic syndrome after treatment with verapamil
EP0968716B1 (en)	2008-12-31	Drugs for ameliorating ocular circulatory disorders
JPH09278653A (ja)	1997-10-28	網膜疾患治療剤
KR100854058B1 (ko)	2008-08-26	스테로이드를 유효 성분으로 하는 망맥락막 질환 치료제
EP1485084B1 (en)	2006-04-05	Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophthalmic topical use capable of improving the level of l-ascorbic acid in the eye
KR20020087834A (ko)	2002-11-23	신경보호 및 망막보호 안과용 약물
US20040259844A1 (en)	2004-12-23	Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
Ajibode	2004	Retinopathy of prematurity: a review
Ferris III	2002	Diabetic macular edema
Bandello et al.	1995	Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy
Marc et al.	1991	Ocular toxicity of topical indomethacin eye drops
AU2002363336A1 (en)	2003-05-19	Methods for treating ocular neovascular diseases